[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8WVfc0ylMzHdJtR2jwUp4HG_eUdW3JXpaFo7_tK2UX8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":82,"rows":89},"Luye Pharma Group Ltd.",[4],74,false,15,12,10414,20,0,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Schizophrenia",10,{"name":18,"count":19},"Parkinson Disease",9,{"name":21,"count":22},"Major Depressive Disorder",7,{"name":24,"count":25},"Healthy",4,{"name":27,"count":25},"Huntington Disease",{"name":29,"count":25},"Schizoaffective Disorder",{"name":31,"count":25},"Alzheimer's Disease Psychosis",{"name":33,"count":34},"Advanced Solid Tumor",3,[36,41,46,51,56,59,64,67,72,77],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06467409","Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery","2025-01","morphine hydrochloride",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07292233","A Food Effect Study of LY03020 in Healthy Subjects","2025-08-27","LY03020",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06980207","A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017","2025-10","LY03017",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06731868","Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia","2025-10-31","LPM3770164 sustained release tablet 5 mg",{"nctId":57,"briefTitle":58,"date":54,"intervention":50},"NCT06793995","Effect of Food and Age on the Pharmacokinetics of LY03017",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07236476","Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)","2025-12-31","LY01021",{"nctId":65,"briefTitle":66,"date":62,"intervention":45},"NCT07230652","A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06240546","First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.","2026-02","LPM6690176",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07371065","To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects","2026-04-30","LY03021",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07516899","Mass Balance Study of [14C] LPM3770164 in Healthy Participants","2026-06-30","[14C] LPM3770164",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,117,158,176,194,212,259,291,324,372,415,437,455,476,494,512,530,569,591,612,632,732,789,838,869,906,931,949,974,999,1017,1035,1053,1080,1098,1133,1159,1228,1258,1288,1330,1352,1391,1409,1427,1445,1473,1491,1513,1540,1558,1576,1594,1618,1644,1662,1688,1706,1724,1742,1767,1792,1810,1828,1853,1871,1889,1914,1932,1950,1975,2000,2018,2036,2054,2072,2095,2113,2139,2157],{"intervention":91,"totalTrials":92,"cells":93},"Toludesvenlafaxine Hydrochloride Sustained-release",1,{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":115},{"trials":95,"activeCount":12},[],{"trials":97,"activeCount":12},[],{"trials":99,"activeCount":12},[],{"trials":101,"activeCount":12},[],{"trials":103,"activeCount":92,"soonestReadout":109},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT06426485","To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets","NOT_YET_RECRUITING",[87],"2027-02-28","2027-06-30","2024-05-30",736,[21],[91],{"trials":116,"activeCount":12},[],{"intervention":118,"totalTrials":119,"cells":120},"Topotecan",2,{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":154,"NA":156},{"trials":122,"activeCount":12},[],{"trials":124,"activeCount":12},[],{"trials":126,"activeCount":12},[],{"trials":128,"activeCount":119,"soonestReadout":146},[129,142],{"nctId":130,"briefTitle":131,"status":132,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT06128837","Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","RECRUITING",[86],"2028-06","2028-10","2024-03-03",686,[139],"Relapsed Small Cell Lung Cancer",[141,118],"Irinotecan hydrochloride liposome",{"nctId":143,"briefTitle":144,"status":132,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":151},"NCT06496048","Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC",[86],"2027-12-31","2028-06-30","2024-09-14",180,[139],[152,153,152,118],"Lurbinectedin","Irinotecan",{"trials":155,"activeCount":12},[],{"trials":157,"activeCount":12},[],{"intervention":141,"totalTrials":92,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":172,"NA":174},{"trials":161,"activeCount":12},[],{"trials":163,"activeCount":12},[],{"trials":165,"activeCount":12},[],{"trials":167,"activeCount":92,"soonestReadout":134},[168],{"nctId":130,"briefTitle":131,"status":132,"phases":169,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":170,"interventions":171},[86],[139],[141,118],{"trials":173,"activeCount":12},[],{"trials":175,"activeCount":12},[],{"intervention":152,"totalTrials":92,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":190,"NA":192},{"trials":179,"activeCount":12},[],{"trials":181,"activeCount":12},[],{"trials":183,"activeCount":12},[],{"trials":185,"activeCount":92,"soonestReadout":146},[186],{"nctId":143,"briefTitle":144,"status":132,"phases":187,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":188,"interventions":189},[86],[139],[152,153,152,118],{"trials":191,"activeCount":12},[],{"trials":193,"activeCount":12},[],{"intervention":153,"totalTrials":92,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":208,"NA":210},{"trials":197,"activeCount":12},[],{"trials":199,"activeCount":12},[],{"trials":201,"activeCount":12},[],{"trials":203,"activeCount":92,"soonestReadout":146},[204],{"nctId":143,"briefTitle":144,"status":132,"phases":205,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":206,"interventions":207},[86],[139],[152,153,152,118],{"trials":209,"activeCount":12},[],{"trials":211,"activeCount":12},[],{"intervention":45,"totalTrials":25,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":243,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":215,"activeCount":12},[],{"trials":217,"activeCount":119,"soonestReadout":44},[218,226,236],{"nctId":42,"briefTitle":43,"status":219,"phases":220,"primaryCompletion":44,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":225},"ACTIVE_NOT_RECRUITING",[84],"2026-03-30","2025-07-30",16,[15,31],[45],{"nctId":227,"briefTitle":228,"status":229,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":235},"NCT06556966","A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects","COMPLETED",[84],"2025-02-13","2024-08-19",66,[15,31],[45],{"nctId":65,"briefTitle":66,"status":132,"phases":237,"primaryCompletion":62,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},[84],"2026-02-28","2025-08-20",40,[15,31],[45],{"trials":244,"activeCount":92,"soonestReadout":146},[245],{"nctId":246,"briefTitle":247,"status":107,"phases":248,"primaryCompletion":146,"completion":146,"start":249,"enrollment":250,"conditions":251,"interventions":252},"NCT07396870","A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia",[85],"2026-03-31",160,[15],[45],{"trials":254,"activeCount":12},[],{"trials":256,"activeCount":12},[],{"trials":258,"activeCount":12},[],{"intervention":71,"totalTrials":119,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":272,"PHASE3":285,"PHASE4":287,"NA":289},{"trials":262,"activeCount":12},[],{"trials":264,"activeCount":92,"soonestReadout":70},[265],{"nctId":68,"briefTitle":69,"status":132,"phases":266,"primaryCompletion":70,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},[84],"2027-02","2024-03-12",102,[33],[71],{"trials":273,"activeCount":92,"soonestReadout":278},[274],{"nctId":275,"briefTitle":276,"status":107,"phases":277,"primaryCompletion":278,"completion":278,"start":249,"enrollment":279,"conditions":280,"interventions":282},"NCT07391566","LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation",[84,85],"2028-12-31",99,[281],"Metastatic Colorectal Cancer (mCRC)",[71,283,284],"Bevacizumab","FOLFIRI",{"trials":286,"activeCount":12},[],{"trials":288,"activeCount":12},[],{"trials":290,"activeCount":12},[],{"intervention":283,"totalTrials":119,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":303,"PHASE4":320,"NA":322},{"trials":294,"activeCount":12},[],{"trials":296,"activeCount":12},[],{"trials":298,"activeCount":92,"soonestReadout":278},[299],{"nctId":275,"briefTitle":276,"status":107,"phases":300,"primaryCompletion":278,"completion":278,"start":249,"enrollment":279,"conditions":301,"interventions":302},[84,85],[281],[71,283,284],{"trials":304,"activeCount":12},[305],{"nctId":306,"briefTitle":307,"status":308,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":318},"NCT03533127","A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer","UNKNOWN",[86],"2020-06-28","2020-12-28","2017-11-27",648,[315,316,317],"Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","Non Small Cell Lung Cancer Recurrent",[319,283],"LY01008",{"trials":321,"activeCount":12},[],{"trials":323,"activeCount":12},[],{"intervention":325,"totalTrials":25,"cells":326},"LPM3480392",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":349,"PHASE3":366,"PHASE4":368,"NA":370},{"trials":328,"activeCount":12},[],{"trials":330,"activeCount":12},[331,340],{"nctId":332,"briefTitle":333,"status":229,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":339},"NCT05857449","An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects",[84],"2022-03-09","2021-11-08",23,[24],[325],{"nctId":341,"briefTitle":342,"status":229,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":348},"NCT05862974","A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects",[84],"2021-11-02","2021-02-25",80,[24],[325],{"trials":350,"activeCount":92,"soonestReadout":39},[351,361],{"nctId":352,"briefTitle":353,"status":229,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT06204120","Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery",[85],"2023-07-04","2022-11-25",150,[359],"Pain, Postoperative",[325,40],{"nctId":37,"briefTitle":38,"status":132,"phases":362,"primaryCompletion":39,"completion":39,"start":363,"enrollment":357,"conditions":364,"interventions":365},[85],"2024-01-26",[359],[40,325,325,325,325],{"trials":367,"activeCount":12},[],{"trials":369,"activeCount":12},[],{"trials":371,"activeCount":12},[],{"intervention":373,"totalTrials":34,"cells":374},"LPM3770164 sustained release tablet simulant",{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":398,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":376,"activeCount":12},[],{"trials":378,"activeCount":12},[379,390],{"nctId":380,"briefTitle":381,"status":229,"phases":382,"primaryCompletion":383,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},"NCT05238701","A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects",[84],"2023-11-04","2022-02-25",104,[27,387],"Tardive Dyskinesia",[389,373],"LPM3770164 sustained release",{"nctId":391,"briefTitle":392,"status":229,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":240,"conditions":396,"interventions":397},"NCT06216054","Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects",[84],"2024-07-29","2023-12-19",[387,27],[389,373],{"trials":399,"activeCount":92,"soonestReadout":54},[400],{"nctId":52,"briefTitle":53,"status":132,"phases":401,"primaryCompletion":54,"completion":54,"start":402,"enrollment":403,"conditions":404,"interventions":406},[84,85],"2025-01-14",120,[405],"Tardive Dyskinesia (TD)",[55,407,408,373],"LPM3770164 sustained release tablet 10 mg","LPM3770164 sustained release tablet 20 mg",{"trials":410,"activeCount":12},[],{"trials":412,"activeCount":12},[],{"trials":414,"activeCount":12},[],{"intervention":40,"totalTrials":119,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":418,"activeCount":12},[],{"trials":420,"activeCount":12},[],{"trials":422,"activeCount":92,"soonestReadout":39},[423,427],{"nctId":352,"briefTitle":353,"status":229,"phases":424,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":425,"interventions":426},[85],[359],[325,40],{"nctId":37,"briefTitle":38,"status":132,"phases":428,"primaryCompletion":39,"completion":39,"start":363,"enrollment":357,"conditions":429,"interventions":430},[85],[359],[40,325,325,325,325],{"trials":432,"activeCount":12},[],{"trials":434,"activeCount":12},[],{"trials":436,"activeCount":12},[],{"intervention":284,"totalTrials":92,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":440,"activeCount":12},[],{"trials":442,"activeCount":12},[],{"trials":444,"activeCount":92,"soonestReadout":278},[445],{"nctId":275,"briefTitle":276,"status":107,"phases":446,"primaryCompletion":278,"completion":278,"start":249,"enrollment":279,"conditions":447,"interventions":448},[84,85],[281],[71,283,284],{"trials":450,"activeCount":12},[],{"trials":452,"activeCount":12},[],{"trials":454,"activeCount":12},[],{"intervention":63,"totalTrials":92,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":458,"activeCount":12},[],{"trials":460,"activeCount":12},[],{"trials":462,"activeCount":92,"soonestReadout":62},[463],{"nctId":60,"briefTitle":61,"status":219,"phases":464,"primaryCompletion":62,"completion":62,"start":465,"enrollment":466,"conditions":467,"interventions":469},[85],"2024-10-09",90,[468],"Assisted Reproduction",[63],{"trials":471,"activeCount":12},[],{"trials":473,"activeCount":12},[],{"trials":475,"activeCount":12},[],{"intervention":55,"totalTrials":92,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":479,"activeCount":12},[],{"trials":481,"activeCount":12},[],{"trials":483,"activeCount":92,"soonestReadout":54},[484],{"nctId":52,"briefTitle":53,"status":132,"phases":485,"primaryCompletion":54,"completion":54,"start":402,"enrollment":403,"conditions":486,"interventions":487},[84,85],[405],[55,407,408,373],{"trials":489,"activeCount":12},[],{"trials":491,"activeCount":12},[],{"trials":493,"activeCount":12},[],{"intervention":407,"totalTrials":92,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":497,"activeCount":12},[],{"trials":499,"activeCount":12},[],{"trials":501,"activeCount":92,"soonestReadout":54},[502],{"nctId":52,"briefTitle":53,"status":132,"phases":503,"primaryCompletion":54,"completion":54,"start":402,"enrollment":403,"conditions":504,"interventions":505},[84,85],[405],[55,407,408,373],{"trials":507,"activeCount":12},[],{"trials":509,"activeCount":12},[],{"trials":511,"activeCount":12},[],{"intervention":408,"totalTrials":92,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":515,"activeCount":12},[],{"trials":517,"activeCount":12},[],{"trials":519,"activeCount":92,"soonestReadout":54},[520],{"nctId":52,"briefTitle":53,"status":132,"phases":521,"primaryCompletion":54,"completion":54,"start":402,"enrollment":403,"conditions":522,"interventions":523},[84,85],[405],[55,407,408,373],{"trials":525,"activeCount":12},[],{"trials":527,"activeCount":12},[],{"trials":529,"activeCount":12},[],{"intervention":50,"totalTrials":34,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":533,"activeCount":12},[],{"trials":535,"activeCount":119,"soonestReadout":49},[536,549,556],{"nctId":537,"briefTitle":538,"status":308,"phases":539,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":547},"NCT06388551","A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017",[84],"2025-03-30","2024-05-10",60,[544,545,546],"Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis","Hallucinations and Delusions Associated With Parkinson Disease Psychosis","Negative Symptoms of Schizophrenia",[50,548],"LY03017-Placebo",{"nctId":57,"briefTitle":58,"status":107,"phases":550,"primaryCompletion":54,"completion":54,"start":551,"enrollment":552,"conditions":553,"interventions":555},[84],"2025-02",26,[31,554,546],"Parkinson Disease Psychosis",[50,50],{"nctId":47,"briefTitle":48,"status":107,"phases":557,"primaryCompletion":49,"completion":49,"start":558,"enrollment":240,"conditions":559,"interventions":560},[84],"2025-05",[544,545,546],[50,548],{"trials":562,"activeCount":12},[],{"trials":564,"activeCount":12},[],{"trials":566,"activeCount":12},[],{"trials":568,"activeCount":12},[],{"intervention":548,"totalTrials":119,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":572,"activeCount":12},[],{"trials":574,"activeCount":92,"soonestReadout":49},[575,579],{"nctId":537,"briefTitle":538,"status":308,"phases":576,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":577,"interventions":578},[84],[544,545,546],[50,548],{"nctId":47,"briefTitle":48,"status":107,"phases":580,"primaryCompletion":49,"completion":49,"start":558,"enrollment":240,"conditions":581,"interventions":582},[84],[544,545,546],[50,548],{"trials":584,"activeCount":12},[],{"trials":586,"activeCount":12},[],{"trials":588,"activeCount":12},[],{"trials":590,"activeCount":12},[],{"intervention":76,"totalTrials":92,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":604,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":594,"activeCount":12},[],{"trials":596,"activeCount":92,"soonestReadout":75},[597],{"nctId":73,"briefTitle":74,"status":598,"phases":599,"primaryCompletion":75,"completion":75,"start":600,"enrollment":601,"conditions":602,"interventions":603},"ENROLLING_BY_INVITATION",[84],"2025-10-28",98,[21],[76],{"trials":605,"activeCount":12},[],{"trials":607,"activeCount":12},[],{"trials":609,"activeCount":12},[],{"trials":611,"activeCount":12},[],{"intervention":81,"totalTrials":92,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":615,"activeCount":12},[],{"trials":617,"activeCount":92,"soonestReadout":80},[618],{"nctId":78,"briefTitle":79,"status":107,"phases":619,"primaryCompletion":80,"completion":620,"start":75,"enrollment":621,"conditions":622,"interventions":623},[84],"2026-07-30",8,[27],[81],{"trials":625,"activeCount":12},[],{"trials":627,"activeCount":12},[],{"trials":629,"activeCount":12},[],{"trials":631,"activeCount":12},[],{"intervention":633,"totalTrials":19,"cells":634},"LY03003",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":714,"PHASE3":716,"PHASE4":728,"NA":730},{"trials":636,"activeCount":12},[],{"trials":638,"activeCount":12},[639,648,657,665,675,686,696,705],{"nctId":640,"briefTitle":641,"status":229,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":647},"NCT04629404","A Clinical Trial to Evaluate the Pharmacodynamics\u002FPharmacokinetics and Safety of LY03003 in Early PD Patients",[84],"2019-03-14","2018-11-05",32,[18],[633],{"nctId":649,"briefTitle":650,"status":229,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":656},"NCT03589066","Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease",[84],"2018-10-31","2018-05-15",24,[18],[633],{"nctId":658,"briefTitle":659,"status":229,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":11,"conditions":663,"interventions":664},"NCT04627155","A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003",[84],"2013-05-20","2013-03-15",[18],[633],{"nctId":666,"briefTitle":667,"status":229,"phases":668,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":674},"NCT04384666","A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers",[84],"2020-08-05","2020-08-10","2020-06-02",56,[18],[633],{"nctId":676,"briefTitle":677,"status":229,"phases":678,"primaryCompletion":679,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":684},"NCT02055274","Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease",[84],"2015-08","2013-10",39,[683],"Parkinson's Disease",[633,685],"Neupro",{"nctId":687,"briefTitle":688,"status":229,"phases":689,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT04630860","A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD",[84],"2021-05-12","2022-01-25","2020-07-07",30,[18],[633],{"nctId":697,"briefTitle":698,"status":229,"phases":699,"primaryCompletion":700,"completion":700,"start":701,"enrollment":240,"conditions":702,"interventions":703},"NCT03733561","A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro",[84],"2018-12-23","2018-11-09",[18],[633,704],"Neupro 4Mg\u002F24Hr Transdermal Patch",{"nctId":706,"briefTitle":707,"status":229,"phases":708,"primaryCompletion":709,"completion":710,"start":711,"enrollment":693,"conditions":712,"interventions":713},"NCT04045678","A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease",[84],"2019-04-16","2019-06-21","2017-10-10",[18],[633],{"trials":715,"activeCount":12},[],{"trials":717,"activeCount":12},[718],{"nctId":719,"briefTitle":720,"status":229,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT04571164","A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD",[86],"2022-03-17","2022-09-27","2020-05-11",294,[18],[633],{"trials":729,"activeCount":12},[],{"trials":731,"activeCount":12},[],{"intervention":733,"totalTrials":25,"cells":734},"LY06006",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":771,"PHASE3":773,"PHASE4":785,"NA":787},{"trials":736,"activeCount":12},[],{"trials":738,"activeCount":12},[739,749,760],{"nctId":740,"briefTitle":741,"status":308,"phases":742,"primaryCompletion":743,"completion":743,"start":744,"enrollment":645,"conditions":745,"interventions":747},"NCT03427853","A Study to Evaluate the Denosumab in Healthy Adults",[84],"2019-12-28","2018-01-10",[746],"Healthy Adults",[733,748],"Placebos",{"nctId":750,"briefTitle":751,"status":308,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":758},"NCT04973722","A Study to Evaluate LY06006 and Prolia in Healthy Adults",[84],"2021-04-10","2021-12-31","2020-12-09",168,[746],[733,759],"Prolia",{"nctId":761,"briefTitle":762,"status":229,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":768},"NCT06095427","A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection",[84],"2023-03-14","2021-03-09",300,[24],[733,769,770],"US-Prolia","EU-Prolia",{"trials":772,"activeCount":12},[],{"trials":774,"activeCount":12},[775],{"nctId":776,"briefTitle":777,"status":308,"phases":778,"primaryCompletion":779,"completion":754,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT05060406","A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture",[86],"2021-09-30","2019-06-30",448,[783],"Postmenopausal Osteoporosis",[733],{"trials":786,"activeCount":12},[],{"trials":788,"activeCount":12},[],{"intervention":790,"totalTrials":34,"cells":791},"LY01005",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":819,"PHASE3":821,"PHASE4":834,"NA":836},{"trials":793,"activeCount":12},[],{"trials":795,"activeCount":12},[796,808],{"nctId":797,"briefTitle":798,"status":229,"phases":799,"primaryCompletion":800,"completion":801,"start":802,"enrollment":803,"conditions":804,"interventions":806},"NCT03450109","A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer",[84],"2018-10-15","2018-10-30","2017-12-22",19,[805],"Cancer of Prostate",[790,807],"Zoladex",{"nctId":809,"briefTitle":810,"status":229,"phases":811,"primaryCompletion":812,"completion":813,"start":814,"enrollment":337,"conditions":815,"interventions":817},"NCT05140512","Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®",[84],"2021-09-15","2021-11-26","2021-02-04",[816],"Prostate Cancer",[790,818],"ZOLADEX® 3.6 mg",{"trials":820,"activeCount":12},[],{"trials":822,"activeCount":12},[823],{"nctId":824,"briefTitle":825,"status":229,"phases":826,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":833},"NCT05110170","Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®",[86],"2022-04-05","2022-06-24","2020-10-15",188,[832],"Breast Cancer",[790,818],{"trials":835,"activeCount":12},[],{"trials":837,"activeCount":12},[],{"intervention":818,"totalTrials":34,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":848,"PHASE3":850,"PHASE4":865,"NA":867},{"trials":841,"activeCount":12},[],{"trials":843,"activeCount":12},[844],{"nctId":809,"briefTitle":810,"status":229,"phases":845,"primaryCompletion":812,"completion":813,"start":814,"enrollment":337,"conditions":846,"interventions":847},[84],[816],[790,818],{"trials":849,"activeCount":12},[],{"trials":851,"activeCount":12},[852,856],{"nctId":824,"briefTitle":825,"status":229,"phases":853,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":854,"interventions":855},[86],[832],[790,818],{"nctId":857,"briefTitle":858,"status":229,"phases":859,"primaryCompletion":765,"completion":765,"start":860,"enrollment":861,"conditions":862,"interventions":863},"NCT04563936","Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®",[86],"2020-01-06",290,[816],[864,818],"LY01005 3.6 mg",{"trials":866,"activeCount":12},[],{"trials":868,"activeCount":12},[],{"intervention":870,"totalTrials":119,"cells":871},"LY01011",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":886,"PHASE3":888,"PHASE4":902,"NA":904},{"trials":873,"activeCount":12},[],{"trials":875,"activeCount":12},[876],{"nctId":877,"briefTitle":878,"status":308,"phases":879,"primaryCompletion":880,"completion":881,"start":882,"enrollment":756,"conditions":883,"interventions":884},"NCT04198636","A Study to Evaluate LY01011 and Xgeva® in Healthy Adults",[84],"2020-12-31","2021-06-30","2019-12-16",[746],[870,885],"Xgeva 120 MG in 1.7 ML",{"trials":887,"activeCount":12},[],{"trials":889,"activeCount":12},[890],{"nctId":891,"briefTitle":892,"status":308,"phases":893,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT04859569","Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors",[86],"2022-12-31","2023-06-30","2021-04-30",850,[899],"Bone Metastases From Solid Tumors",[870,901],"Xgeva®",{"trials":903,"activeCount":12},[],{"trials":905,"activeCount":12},[],{"intervention":907,"totalTrials":92,"cells":908},"Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":927,"NA":929},{"trials":910,"activeCount":12},[],{"trials":912,"activeCount":12},[],{"trials":914,"activeCount":12},[],{"trials":916,"activeCount":12},[917],{"nctId":918,"briefTitle":919,"status":308,"phases":920,"primaryCompletion":75,"completion":75,"start":921,"enrollment":922,"conditions":923,"interventions":925},"NCT05970510","A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.",[86],"2023-07-12",555,[924],"Generalized Anxiety Disorder",[907,926],"Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg",{"trials":928,"activeCount":12},[],{"trials":930,"activeCount":12},[],{"intervention":926,"totalTrials":92,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":945,"NA":947},{"trials":934,"activeCount":12},[],{"trials":936,"activeCount":12},[],{"trials":938,"activeCount":12},[],{"trials":940,"activeCount":12},[941],{"nctId":918,"briefTitle":919,"status":308,"phases":942,"primaryCompletion":75,"completion":75,"start":921,"enrollment":922,"conditions":943,"interventions":944},[86],[924],[907,926],{"trials":946,"activeCount":12},[],{"trials":948,"activeCount":12},[],{"intervention":950,"totalTrials":92,"cells":951},"LY03005 extended-release",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":970,"NA":972},{"trials":953,"activeCount":12},[],{"trials":955,"activeCount":12},[],{"trials":957,"activeCount":12},[],{"trials":959,"activeCount":12},[960],{"nctId":961,"briefTitle":962,"status":229,"phases":963,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":969},"NCT04853407","A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)",[86],"2020-12-24","2018-12-05",558,[968],"Major Depressive Disorder (MDD)",[950],{"trials":971,"activeCount":12},[],{"trials":973,"activeCount":12},[],{"intervention":975,"totalTrials":92,"cells":976},"Denosumab",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":995,"NA":997},{"trials":978,"activeCount":12},[],{"trials":980,"activeCount":12},[],{"trials":982,"activeCount":12},[],{"trials":984,"activeCount":12},[985],{"nctId":986,"briefTitle":987,"status":308,"phases":988,"primaryCompletion":222,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":994},"NCT05853354","Comparative Efficacy, Safety, PK, and Immunogenicity Study",[86],"2025-12-30","2023-04-05",392,[993],"Osteoporosis, Postmenopausal",[975],{"trials":996,"activeCount":12},[],{"trials":998,"activeCount":12},[],{"intervention":901,"totalTrials":92,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1013,"NA":1015},{"trials":1002,"activeCount":12},[],{"trials":1004,"activeCount":12},[],{"trials":1006,"activeCount":12},[],{"trials":1008,"activeCount":12},[1009],{"nctId":891,"briefTitle":892,"status":308,"phases":1010,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":1011,"interventions":1012},[86],[899],[870,901],{"trials":1014,"activeCount":12},[],{"trials":1016,"activeCount":12},[],{"intervention":864,"totalTrials":92,"cells":1018},{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1025,"PHASE4":1031,"NA":1033},{"trials":1020,"activeCount":12},[],{"trials":1022,"activeCount":12},[],{"trials":1024,"activeCount":12},[],{"trials":1026,"activeCount":12},[1027],{"nctId":857,"briefTitle":858,"status":229,"phases":1028,"primaryCompletion":765,"completion":765,"start":860,"enrollment":861,"conditions":1029,"interventions":1030},[86],[816],[864,818],{"trials":1032,"activeCount":12},[],{"trials":1034,"activeCount":12},[],{"intervention":319,"totalTrials":92,"cells":1036},{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1049,"NA":1051},{"trials":1038,"activeCount":12},[],{"trials":1040,"activeCount":12},[],{"trials":1042,"activeCount":12},[],{"trials":1044,"activeCount":12},[1045],{"nctId":306,"briefTitle":307,"status":308,"phases":1046,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":1047,"interventions":1048},[86],[315,316,317],[319,283],{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":12},[],{"intervention":1054,"totalTrials":92,"cells":1055},"LY09004",{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1062,"PHASE4":1076,"NA":1078},{"trials":1057,"activeCount":12},[],{"trials":1059,"activeCount":12},[],{"trials":1061,"activeCount":12},[],{"trials":1063,"activeCount":12},[1064],{"nctId":1065,"briefTitle":1066,"status":308,"phases":1067,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1074},"NCT04572698","A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）",[86],"2023-06","2023-12","2020-11",416,[1073],"Age Related Macular Degeneration",[1054,1075],"Eylea",{"trials":1077,"activeCount":12},[],{"trials":1079,"activeCount":12},[],{"intervention":1075,"totalTrials":92,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1094,"NA":1096},{"trials":1083,"activeCount":12},[],{"trials":1085,"activeCount":12},[],{"trials":1087,"activeCount":12},[],{"trials":1089,"activeCount":12},[1090],{"nctId":1065,"briefTitle":1066,"status":308,"phases":1091,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1092,"interventions":1093},[86],[1073],[1054,1075],{"trials":1095,"activeCount":12},[],{"trials":1097,"activeCount":12},[],{"intervention":1099,"totalTrials":119,"cells":1100},"LY01610",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1116,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1102,"activeCount":12},[],{"trials":1104,"activeCount":12},[1105],{"nctId":1106,"briefTitle":1107,"status":229,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1113},"NCT04088604","Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors",[84],"2021-12-17","2019-02-15",38,[33],[1099,1114,1115],"LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）","Irinotecan Hydrochloride Injection（CAMPTO®）",{"trials":1117,"activeCount":12},[1118],{"nctId":1119,"briefTitle":1120,"status":229,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":233,"conditions":1124,"interventions":1126},"NCT04381910","Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer",[85],"2023-03-04","2020-09-28",[1125],"Small Cell Lung Cancer",[1099],{"trials":1128,"activeCount":12},[],{"trials":1130,"activeCount":12},[],{"trials":1132,"activeCount":12},[],{"intervention":1134,"totalTrials":92,"cells":1135},"LY010616",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1137,"activeCount":12},[],{"trials":1139,"activeCount":12},[],{"trials":1141,"activeCount":12},[1142],{"nctId":1143,"briefTitle":1144,"status":308,"phases":1145,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1152},"NCT05865925","Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors",[84,85],"2024-08-31","2024-10-30","2021-04-22",78,[1151],"Advanced Solid Tumors",[1134],{"trials":1154,"activeCount":12},[],{"trials":1156,"activeCount":12},[],{"trials":1158,"activeCount":12},[],{"intervention":1160,"totalTrials":1161,"cells":1162},"LY03005",6,{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1164,"activeCount":12},[],{"trials":1166,"activeCount":12},[1167,1174,1184,1193,1202,1211],{"nctId":1168,"briefTitle":1169,"status":229,"phases":1170,"primaryCompletion":802,"completion":802,"start":312,"enrollment":11,"conditions":1171,"interventions":1172},"NCT03357796","Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®",[84],[21],[1160,1173],"Pristiq",{"nctId":1175,"briefTitle":1176,"status":229,"phases":1177,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT02271412","Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005",[84],"2015-03","2014-10",58,[1182],"Major Depressive Disorder, Recurrent, Unspecified",[1160],{"nctId":1185,"briefTitle":1186,"status":229,"phases":1187,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":1190,"conditions":1191,"interventions":1192},"NCT02055300","Safety, Tolerability and Pharmacokinetics Study of LY03005",[84],"2014-08","2014-02",88,[21],[1160,1173],{"nctId":1194,"briefTitle":1195,"status":229,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1201},"NCT03822065","A Relative Bioavailability Food Effect Study of LY03005",[84],"2019-02-16","2019-01-16",34,[21],[1160],{"nctId":1203,"briefTitle":1204,"status":229,"phases":1205,"primaryCompletion":1206,"completion":1206,"start":1207,"enrollment":11,"conditions":1208,"interventions":1210},"NCT02988024","Pilot BA Study of New LY03005 vs Pristiq",[84],"2016-12-28","2016-12-07",[1209],"Major Depression",[1160,1173],{"nctId":1212,"briefTitle":1213,"status":229,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":672,"conditions":1218,"interventions":1219},"NCT03733574","A Study of LY03005 vs Pristiq",[84],"2018-07-17","2018-07-26","2018-06-19",[21],[1160,1173],{"trials":1221,"activeCount":12},[],{"trials":1223,"activeCount":12},[],{"trials":1225,"activeCount":12},[],{"trials":1227,"activeCount":12},[],{"intervention":1173,"totalTrials":25,"cells":1229},{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1231,"activeCount":12},[],{"trials":1233,"activeCount":12},[1234,1238,1242,1246],{"nctId":1168,"briefTitle":1169,"status":229,"phases":1235,"primaryCompletion":802,"completion":802,"start":312,"enrollment":11,"conditions":1236,"interventions":1237},[84],[21],[1160,1173],{"nctId":1185,"briefTitle":1186,"status":229,"phases":1239,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":1190,"conditions":1240,"interventions":1241},[84],[21],[1160,1173],{"nctId":1203,"briefTitle":1204,"status":229,"phases":1243,"primaryCompletion":1206,"completion":1206,"start":1207,"enrollment":11,"conditions":1244,"interventions":1245},[84],[1209],[1160,1173],{"nctId":1212,"briefTitle":1213,"status":229,"phases":1247,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":672,"conditions":1248,"interventions":1249},[84],[21],[1160,1173],{"trials":1251,"activeCount":12},[],{"trials":1253,"activeCount":12},[],{"trials":1255,"activeCount":12},[],{"trials":1257,"activeCount":12},[],{"intervention":389,"totalTrials":34,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1280,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1261,"activeCount":12},[],{"trials":1263,"activeCount":12},[1264,1272,1276],{"nctId":1265,"briefTitle":1266,"status":229,"phases":1267,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":223,"conditions":1270,"interventions":1271},"NCT06474650","Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets",[84],"2024-09-25","2024-07-31",[27,387],[389],{"nctId":380,"briefTitle":381,"status":229,"phases":1273,"primaryCompletion":383,"completion":383,"start":384,"enrollment":385,"conditions":1274,"interventions":1275},[84],[27,387],[389,373],{"nctId":391,"briefTitle":392,"status":229,"phases":1277,"primaryCompletion":394,"completion":394,"start":395,"enrollment":240,"conditions":1278,"interventions":1279},[84],[387,27],[389,373],{"trials":1281,"activeCount":12},[],{"trials":1283,"activeCount":12},[],{"trials":1285,"activeCount":12},[],{"trials":1287,"activeCount":12},[],{"intervention":1289,"totalTrials":34,"cells":1290},"LY03004",{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1322,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1292,"activeCount":12},[],{"trials":1294,"activeCount":12},[1295,1305,1314],{"nctId":1296,"briefTitle":1297,"status":229,"phases":1298,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":1301,"conditions":1302,"interventions":1303},"NCT02091388","Bioavailability of LY03004 and Risperdal® Consta®",[84],"2015-01","2014-09",108,[15,29],[1289,1304],"Risperdal® Consta®",{"nctId":1306,"briefTitle":1307,"status":229,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1311,"conditions":1312,"interventions":1313},"NCT02055287","Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder",[84],"2014-06","2013-03",36,[15,29],[1289],{"nctId":1315,"briefTitle":1316,"status":229,"phases":1317,"primaryCompletion":1318,"completion":1318,"start":1319,"enrollment":223,"conditions":1320,"interventions":1321},"NCT02186769","An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder",[84],"2015-04","2014-07",[15,29],[1304,1289],{"trials":1323,"activeCount":12},[],{"trials":1325,"activeCount":12},[],{"trials":1327,"activeCount":12},[],{"trials":1329,"activeCount":12},[],{"intervention":1304,"totalTrials":119,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1344,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1333,"activeCount":12},[],{"trials":1335,"activeCount":12},[1336,1340],{"nctId":1296,"briefTitle":1297,"status":229,"phases":1337,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":1301,"conditions":1338,"interventions":1339},[84],[15,29],[1289,1304],{"nctId":1315,"briefTitle":1316,"status":229,"phases":1341,"primaryCompletion":1318,"completion":1318,"start":1319,"enrollment":223,"conditions":1342,"interventions":1343},[84],[15,29],[1304,1289],{"trials":1345,"activeCount":12},[],{"trials":1347,"activeCount":12},[],{"trials":1349,"activeCount":12},[],{"trials":1351,"activeCount":12},[],{"intervention":1353,"totalTrials":92,"cells":1354},"LY03010 156 mg treatment group, deltoid",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1383,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1356,"activeCount":12},[],{"trials":1358,"activeCount":12},[1359],{"nctId":1360,"briefTitle":1361,"status":229,"phases":1362,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1379},"NCT05321602","Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder",[84],"2022-09-23","2022-10-23","2021-09-08",89,[15,1368,1369,1370,1371,1372,1373,1374,1375,1376,1377,1378],"Psychotic Disorders","Mood Disorders","Schizophrenia Spectrum and Other Psychotic Disorders","Mental Disorders","Antipsychotic Agents","Tranquilizing Agents","Central Nervous System Depression","Physiological Effects of Drugs","Psychotropic Drugs","Neurotransmitter Agents","Molecular Mechanisms of Pharmacological Action",[1353,1380,1381,1382],"LY03010 156 mg treatment group, gluteal","LY03010 351 mg treatment group, deltoid","LY03010 351 mg treatment group, gluteal",{"trials":1384,"activeCount":12},[],{"trials":1386,"activeCount":12},[],{"trials":1388,"activeCount":12},[],{"trials":1390,"activeCount":12},[],{"intervention":1380,"totalTrials":92,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1401,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1394,"activeCount":12},[],{"trials":1396,"activeCount":12},[1397],{"nctId":1360,"briefTitle":1361,"status":229,"phases":1398,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":1399,"interventions":1400},[84],[15,1368,1369,1370,1371,1372,1373,1374,1375,1376,1377,1378],[1353,1380,1381,1382],{"trials":1402,"activeCount":12},[],{"trials":1404,"activeCount":12},[],{"trials":1406,"activeCount":12},[],{"trials":1408,"activeCount":12},[],{"intervention":1381,"totalTrials":92,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1412,"activeCount":12},[],{"trials":1414,"activeCount":12},[1415],{"nctId":1360,"briefTitle":1361,"status":229,"phases":1416,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":1417,"interventions":1418},[84],[15,1368,1369,1370,1371,1372,1373,1374,1375,1376,1377,1378],[1353,1380,1381,1382],{"trials":1420,"activeCount":12},[],{"trials":1422,"activeCount":12},[],{"trials":1424,"activeCount":12},[],{"trials":1426,"activeCount":12},[],{"intervention":1382,"totalTrials":92,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":12},[],{"trials":1432,"activeCount":12},[1433],{"nctId":1360,"briefTitle":1361,"status":229,"phases":1434,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":1435,"interventions":1436},[84],[15,1368,1369,1370,1371,1372,1373,1374,1375,1376,1377,1378],[1353,1380,1381,1382],{"trials":1438,"activeCount":12},[],{"trials":1440,"activeCount":12},[],{"trials":1442,"activeCount":12},[],{"trials":1444,"activeCount":12},[],{"intervention":1446,"totalTrials":92,"cells":1447},"LY03010; paliperidone palmitate",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1449,"activeCount":12},[],{"trials":1451,"activeCount":12},[1452],{"nctId":1453,"briefTitle":1454,"status":229,"phases":1455,"primaryCompletion":1456,"completion":1457,"start":1458,"enrollment":1459,"conditions":1460,"interventions":1463},"NCT04922593","Relative Bioavailability of LY03010 Compared to Listed Drug",[84],"2022-03-15","2022-04-15","2021-01-13",281,[15,1368,1369,1461,1371,1372,1373,1462,1375,1376,1377,1378],"Schizophrenia Spectrum","Central Nervous System Depressants",[1446,1464],"INVEGA SUSTENNA",{"trials":1466,"activeCount":12},[],{"trials":1468,"activeCount":12},[],{"trials":1470,"activeCount":12},[],{"trials":1472,"activeCount":12},[],{"intervention":1464,"totalTrials":92,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1483,"PHASE3":1485,"PHASE4":1487,"NA":1489},{"trials":1476,"activeCount":12},[],{"trials":1478,"activeCount":12},[1479],{"nctId":1453,"briefTitle":1454,"status":229,"phases":1480,"primaryCompletion":1456,"completion":1457,"start":1458,"enrollment":1459,"conditions":1481,"interventions":1482},[84],[15,1368,1369,1461,1371,1372,1373,1462,1375,1376,1377,1378],[1446,1464],{"trials":1484,"activeCount":12},[],{"trials":1486,"activeCount":12},[],{"trials":1488,"activeCount":12},[],{"trials":1490,"activeCount":12},[],{"intervention":1492,"totalTrials":92,"cells":1493},"Lurbinectedin for",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1505,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1495,"activeCount":12},[],{"trials":1497,"activeCount":12},[1498],{"nctId":1499,"briefTitle":1500,"status":229,"phases":1501,"primaryCompletion":383,"completion":383,"start":1502,"enrollment":645,"conditions":1503,"interventions":1504},"NCT04638491","Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients",[84],"2020-11-24",[33],[1492],{"trials":1506,"activeCount":12},[],{"trials":1508,"activeCount":12},[],{"trials":1510,"activeCount":12},[],{"trials":1512,"activeCount":12},[],{"intervention":1514,"totalTrials":92,"cells":1515},"LY03005 extended-release tablets 40 mg",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1532,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1517,"activeCount":12},[],{"trials":1519,"activeCount":12},[1520],{"nctId":1521,"briefTitle":1522,"status":229,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1528},"NCT03785652","Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)",[84],"2015-10-31","2015-10-09",260,[21],[1514,1529,1530,1531],"LY03005 extended-release tablets 80 mg group","LY03005 extended-release tablets 120 mg group","LY03005 extended-release tablets 160 mg group",{"trials":1533,"activeCount":12},[],{"trials":1535,"activeCount":12},[],{"trials":1537,"activeCount":12},[],{"trials":1539,"activeCount":12},[],{"intervention":1529,"totalTrials":92,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1543,"activeCount":12},[],{"trials":1545,"activeCount":12},[1546],{"nctId":1521,"briefTitle":1522,"status":229,"phases":1547,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1548,"interventions":1549},[84],[21],[1514,1529,1530,1531],{"trials":1551,"activeCount":12},[],{"trials":1553,"activeCount":12},[],{"trials":1555,"activeCount":12},[],{"trials":1557,"activeCount":12},[],{"intervention":1530,"totalTrials":92,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1568,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1561,"activeCount":12},[],{"trials":1563,"activeCount":12},[1564],{"nctId":1521,"briefTitle":1522,"status":229,"phases":1565,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1566,"interventions":1567},[84],[21],[1514,1529,1530,1531],{"trials":1569,"activeCount":12},[],{"trials":1571,"activeCount":12},[],{"trials":1573,"activeCount":12},[],{"trials":1575,"activeCount":12},[],{"intervention":1531,"totalTrials":92,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1586,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1579,"activeCount":12},[],{"trials":1581,"activeCount":12},[1582],{"nctId":1521,"briefTitle":1522,"status":229,"phases":1583,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1584,"interventions":1585},[84],[21],[1514,1529,1530,1531],{"trials":1587,"activeCount":12},[],{"trials":1589,"activeCount":12},[],{"trials":1591,"activeCount":12},[],{"trials":1593,"activeCount":12},[],{"intervention":1595,"totalTrials":92,"cells":1596},"Rotigotine, extended-release microspheres",{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1610,"PHASE3":1612,"PHASE4":1614,"NA":1616},{"trials":1598,"activeCount":12},[],{"trials":1600,"activeCount":12},[1601],{"nctId":1602,"briefTitle":1603,"status":229,"phases":1604,"primaryCompletion":1605,"completion":1606,"start":1607,"enrollment":542,"conditions":1608,"interventions":1609},"NCT04044547","A Study of LY03003 in Patients With Early-stage Parkinson's Disease",[84],"2014-02-26","2015-06-11","2013-11-22",[18],[1595],{"trials":1611,"activeCount":12},[],{"trials":1613,"activeCount":12},[],{"trials":1615,"activeCount":12},[],{"trials":1617,"activeCount":12},[],{"intervention":1619,"totalTrials":92,"cells":1620},"LY-CovMab",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1622,"activeCount":12},[],{"trials":1624,"activeCount":12},[1625],{"nctId":1626,"briefTitle":1627,"status":308,"phases":1628,"primaryCompletion":1629,"completion":1630,"start":1631,"enrollment":1632,"conditions":1633,"interventions":1635},"NCT04973735","A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects",[84],"2021-05-01","2021-07-31","2020-11-10",42,[1634],"Covid19",[1619],{"trials":1637,"activeCount":12},[],{"trials":1639,"activeCount":12},[],{"trials":1641,"activeCount":12},[],{"trials":1643,"activeCount":12},[],{"intervention":748,"totalTrials":92,"cells":1645},{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1647,"activeCount":12},[],{"trials":1649,"activeCount":12},[1650],{"nctId":740,"briefTitle":741,"status":308,"phases":1651,"primaryCompletion":743,"completion":743,"start":744,"enrollment":645,"conditions":1652,"interventions":1653},[84],[746],[733,748],{"trials":1655,"activeCount":12},[],{"trials":1657,"activeCount":12},[],{"trials":1659,"activeCount":12},[],{"trials":1661,"activeCount":12},[],{"intervention":1663,"totalTrials":92,"cells":1664},"LY03009 F1",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1666,"activeCount":12},[],{"trials":1668,"activeCount":12},[1669],{"nctId":1670,"briefTitle":1671,"status":308,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":240,"conditions":1675,"interventions":1676},"NCT04593511","to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers",[84],"2021-10","2021-02-02",[683],[1663,1677,1678,1679],"LY03009 F2","LY03009 F3","LY03009 F4",{"trials":1681,"activeCount":12},[],{"trials":1683,"activeCount":12},[],{"trials":1685,"activeCount":12},[],{"trials":1687,"activeCount":12},[],{"intervention":1677,"totalTrials":92,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1691,"activeCount":12},[],{"trials":1693,"activeCount":12},[1694],{"nctId":1670,"briefTitle":1671,"status":308,"phases":1695,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":240,"conditions":1696,"interventions":1697},[84],[683],[1663,1677,1678,1679],{"trials":1699,"activeCount":12},[],{"trials":1701,"activeCount":12},[],{"trials":1703,"activeCount":12},[],{"trials":1705,"activeCount":12},[],{"intervention":1678,"totalTrials":92,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1709,"activeCount":12},[],{"trials":1711,"activeCount":12},[1712],{"nctId":1670,"briefTitle":1671,"status":308,"phases":1713,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":240,"conditions":1714,"interventions":1715},[84],[683],[1663,1677,1678,1679],{"trials":1717,"activeCount":12},[],{"trials":1719,"activeCount":12},[],{"trials":1721,"activeCount":12},[],{"trials":1723,"activeCount":12},[],{"intervention":1679,"totalTrials":92,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1727,"activeCount":12},[],{"trials":1729,"activeCount":12},[1730],{"nctId":1670,"briefTitle":1671,"status":308,"phases":1731,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":240,"conditions":1732,"interventions":1733},[84],[683],[1663,1677,1678,1679],{"trials":1735,"activeCount":12},[],{"trials":1737,"activeCount":12},[],{"trials":1739,"activeCount":12},[],{"trials":1741,"activeCount":12},[],{"intervention":1743,"totalTrials":92,"cells":1744},"Doxorubicin hydrochloride liposome",{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1759,"PHASE3":1761,"PHASE4":1763,"NA":1765},{"trials":1746,"activeCount":12},[],{"trials":1748,"activeCount":12},[1749],{"nctId":1750,"briefTitle":1751,"status":229,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT06098599","Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer",[84],"2023-02-09","2022-05-17",48,[1757],"Advanced Breast Cancer",[1743],{"trials":1760,"activeCount":12},[],{"trials":1762,"activeCount":12},[],{"trials":1764,"activeCount":12},[],{"trials":1766,"activeCount":12},[],{"intervention":1768,"totalTrials":92,"cells":1769},"LY03010",{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1771,"activeCount":12},[],{"trials":1773,"activeCount":12},[1774],{"nctId":1775,"briefTitle":1776,"status":229,"phases":1777,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1755,"conditions":1780,"interventions":1782},"NCT03751488","A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients",[84],"2019-07-24","2018-12-12",[1781,15,29],"Schizo Affective Disorder",[1768,1783],"Invega Sustenna 156 MG in 1 ML Prefilled Syringe",{"trials":1785,"activeCount":12},[],{"trials":1787,"activeCount":12},[],{"trials":1789,"activeCount":12},[],{"trials":1791,"activeCount":12},[],{"intervention":1783,"totalTrials":92,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1795,"activeCount":12},[],{"trials":1797,"activeCount":12},[1798],{"nctId":1775,"briefTitle":1776,"status":229,"phases":1799,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1755,"conditions":1800,"interventions":1801},[84],[1781,15,29],[1768,1783],{"trials":1803,"activeCount":12},[],{"trials":1805,"activeCount":12},[],{"trials":1807,"activeCount":12},[],{"trials":1809,"activeCount":12},[],{"intervention":759,"totalTrials":92,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1813,"activeCount":12},[],{"trials":1815,"activeCount":12},[1816],{"nctId":750,"briefTitle":751,"status":308,"phases":1817,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":1818,"interventions":1819},[84],[746],[733,759],{"trials":1821,"activeCount":12},[],{"trials":1823,"activeCount":12},[],{"trials":1825,"activeCount":12},[],{"trials":1827,"activeCount":12},[],{"intervention":1829,"totalTrials":92,"cells":1830},"ROTIGOTINE",{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1845,"PHASE3":1847,"PHASE4":1849,"NA":1851},{"trials":1832,"activeCount":12},[],{"trials":1834,"activeCount":12},[1835],{"nctId":1836,"briefTitle":1837,"status":229,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":1843,"interventions":1844},"NCT02728947","Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg\u002FDay Weekly in Patients With Early-stage Parkinson's Disease",[84],"2016-08","2016-09","2016-05",28,[683],[1829],{"trials":1846,"activeCount":12},[],{"trials":1848,"activeCount":12},[],{"trials":1850,"activeCount":12},[],{"trials":1852,"activeCount":12},[],{"intervention":769,"totalTrials":92,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1863,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1856,"activeCount":12},[],{"trials":1858,"activeCount":12},[1859],{"nctId":761,"briefTitle":762,"status":229,"phases":1860,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":1861,"interventions":1862},[84],[24],[733,769,770],{"trials":1864,"activeCount":12},[],{"trials":1866,"activeCount":12},[],{"trials":1868,"activeCount":12},[],{"trials":1870,"activeCount":12},[],{"intervention":770,"totalTrials":92,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1881,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":12},[],{"trials":1876,"activeCount":12},[1877],{"nctId":761,"briefTitle":762,"status":229,"phases":1878,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":1879,"interventions":1880},[84],[24],[733,769,770],{"trials":1882,"activeCount":12},[],{"trials":1884,"activeCount":12},[],{"trials":1886,"activeCount":12},[],{"trials":1888,"activeCount":12},[],{"intervention":1890,"totalTrials":92,"cells":1891},"RID-TDS 13.3 mg\u002F24 h",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1906,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1893,"activeCount":12},[],{"trials":1895,"activeCount":12},[1896],{"nctId":1897,"briefTitle":1898,"status":229,"phases":1899,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":1755,"conditions":1903,"interventions":1904},"NCT05853341","Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg\u002F24h)",[84],"2023-07-02","2023-07-17","2023-05-02",[24],[1890,1905],"Exelon® 13.3 mg\u002F24 h",{"trials":1907,"activeCount":12},[],{"trials":1909,"activeCount":12},[],{"trials":1911,"activeCount":12},[],{"trials":1913,"activeCount":12},[],{"intervention":1905,"totalTrials":92,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1924,"PHASE3":1926,"PHASE4":1928,"NA":1930},{"trials":1917,"activeCount":12},[],{"trials":1919,"activeCount":12},[1920],{"nctId":1897,"briefTitle":1898,"status":229,"phases":1921,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":1755,"conditions":1922,"interventions":1923},[84],[24],[1890,1905],{"trials":1925,"activeCount":12},[],{"trials":1927,"activeCount":12},[],{"trials":1929,"activeCount":12},[],{"trials":1931,"activeCount":12},[],{"intervention":885,"totalTrials":92,"cells":1933},{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1942,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1935,"activeCount":12},[],{"trials":1937,"activeCount":12},[1938],{"nctId":877,"briefTitle":878,"status":308,"phases":1939,"primaryCompletion":880,"completion":881,"start":882,"enrollment":756,"conditions":1940,"interventions":1941},[84],[746],[870,885],{"trials":1943,"activeCount":12},[],{"trials":1945,"activeCount":12},[],{"trials":1947,"activeCount":12},[],{"trials":1949,"activeCount":12},[],{"intervention":1951,"totalTrials":92,"cells":1952},"Paliperidone Palmitate",{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1967,"PHASE3":1969,"PHASE4":1971,"NA":1973},{"trials":1954,"activeCount":12},[],{"trials":1956,"activeCount":12},[1957],{"nctId":1958,"briefTitle":1959,"status":229,"phases":1960,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":1311,"conditions":1964,"interventions":1966},"NCT04572685","Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients",[84],"2020-06-26","2020-08-20","2020-01-22",[1965],"Schizophrenia Patients",[1951],{"trials":1968,"activeCount":12},[],{"trials":1970,"activeCount":12},[],{"trials":1972,"activeCount":12},[],{"trials":1974,"activeCount":12},[],{"intervention":1976,"totalTrials":92,"cells":1977},"LPM3480226",{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1979,"activeCount":12},[],{"trials":1981,"activeCount":12},[1982],{"nctId":1983,"briefTitle":1984,"status":308,"phases":1985,"primaryCompletion":1986,"completion":1987,"start":1988,"enrollment":693,"conditions":1989,"interventions":1991},"NCT03844438","A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors",[84],"2020-10-28","2022-03-01","2018-12-18",[1990],"Solid Tumor",[1976],{"trials":1993,"activeCount":12},[],{"trials":1995,"activeCount":12},[],{"trials":1997,"activeCount":12},[],{"trials":1999,"activeCount":12},[],{"intervention":1114,"totalTrials":92,"cells":2001},{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2003,"activeCount":12},[],{"trials":2005,"activeCount":12},[2006],{"nctId":1106,"briefTitle":1107,"status":229,"phases":2007,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":2008,"interventions":2009},[84],[33],[1099,1114,1115],{"trials":2011,"activeCount":12},[],{"trials":2013,"activeCount":12},[],{"trials":2015,"activeCount":12},[],{"trials":2017,"activeCount":12},[],{"intervention":1115,"totalTrials":92,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2028,"PHASE3":2030,"PHASE4":2032,"NA":2034},{"trials":2021,"activeCount":12},[],{"trials":2023,"activeCount":12},[2024],{"nctId":1106,"briefTitle":1107,"status":229,"phases":2025,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":2026,"interventions":2027},[84],[33],[1099,1114,1115],{"trials":2029,"activeCount":12},[],{"trials":2031,"activeCount":12},[],{"trials":2033,"activeCount":12},[],{"trials":2035,"activeCount":12},[],{"intervention":685,"totalTrials":92,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2046,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2039,"activeCount":12},[],{"trials":2041,"activeCount":12},[2042],{"nctId":676,"briefTitle":677,"status":229,"phases":2043,"primaryCompletion":679,"completion":679,"start":680,"enrollment":681,"conditions":2044,"interventions":2045},[84],[683],[633,685],{"trials":2047,"activeCount":12},[],{"trials":2049,"activeCount":12},[],{"trials":2051,"activeCount":12},[],{"trials":2053,"activeCount":12},[],{"intervention":807,"totalTrials":92,"cells":2055},{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2064,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2057,"activeCount":12},[],{"trials":2059,"activeCount":12},[2060],{"nctId":797,"briefTitle":798,"status":229,"phases":2061,"primaryCompletion":800,"completion":801,"start":802,"enrollment":803,"conditions":2062,"interventions":2063},[84],[805],[790,807],{"trials":2065,"activeCount":12},[],{"trials":2067,"activeCount":12},[],{"trials":2069,"activeCount":12},[],{"trials":2071,"activeCount":12},[],{"intervention":2073,"totalTrials":92,"cells":2074},"Goserelin Acetate Sustained-Release Microspheres for",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2087,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2076,"activeCount":12},[],{"trials":2078,"activeCount":12},[2079],{"nctId":2080,"briefTitle":2081,"status":308,"phases":2082,"primaryCompletion":1069,"completion":1069,"start":2083,"enrollment":654,"conditions":2084,"interventions":2085},"NCT05856630","Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg",[84],"2023-05",[816],[2073,2086],"Zoladex 10.8 MG Drug Implant",{"trials":2088,"activeCount":12},[],{"trials":2090,"activeCount":12},[],{"trials":2092,"activeCount":12},[],{"trials":2094,"activeCount":12},[],{"intervention":2086,"totalTrials":92,"cells":2096},{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2105,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2098,"activeCount":12},[],{"trials":2100,"activeCount":12},[2101],{"nctId":2080,"briefTitle":2081,"status":308,"phases":2102,"primaryCompletion":1069,"completion":1069,"start":2083,"enrollment":654,"conditions":2103,"interventions":2104},[84],[816],[2073,2086],{"trials":2106,"activeCount":12},[],{"trials":2108,"activeCount":12},[],{"trials":2110,"activeCount":12},[],{"trials":2112,"activeCount":12},[],{"intervention":2114,"totalTrials":92,"cells":2115},"XueZhiKang",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2117,"activeCount":12},[],{"trials":2119,"activeCount":12},[2120],{"nctId":2121,"briefTitle":2122,"status":229,"phases":2123,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":11,"conditions":2127,"interventions":2129},"NCT02603770","Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers",[84],"2016-01","2016-02","2015-11",[2128],"Lipid Metabolism Disorder",[2114,2130],"Lovastatin",{"trials":2132,"activeCount":12},[],{"trials":2134,"activeCount":12},[],{"trials":2136,"activeCount":12},[],{"trials":2138,"activeCount":12},[],{"intervention":2130,"totalTrials":92,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":12},[],{"trials":2144,"activeCount":12},[2145],{"nctId":2121,"briefTitle":2122,"status":229,"phases":2146,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":11,"conditions":2147,"interventions":2148},[84],[2128],[2114,2130],{"trials":2150,"activeCount":12},[],{"trials":2152,"activeCount":12},[],{"trials":2154,"activeCount":12},[],{"trials":2156,"activeCount":12},[],{"intervention":704,"totalTrials":92,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2167,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2160,"activeCount":12},[],{"trials":2162,"activeCount":12},[2163],{"nctId":697,"briefTitle":698,"status":229,"phases":2164,"primaryCompletion":700,"completion":700,"start":701,"enrollment":240,"conditions":2165,"interventions":2166},[84],[18],[633,704],{"trials":2168,"activeCount":12},[],{"trials":2170,"activeCount":12},[],{"trials":2172,"activeCount":12},[],{"trials":2174,"activeCount":12},[]]